Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (daNIS-3)
An Open-label, Multi-center, ph II Platform Study Evaluating the Efficacy and Safety of NIS793 and Other New Investigational Drug Combinations With SOC Anti-cancer Therapy for the 2L Treatment of Metastatic Colorectal Cancer (mCRC)
Sponsor: Novartis Pharmaceuticals
Terminated
The study was terminated early due to the halt of NIS793 treatment and urgent safety measures issued in July and August 2023, respectively, as continued evaluation of Standard of Care alone will not support the trial's purpose.
Other terminated trials from Novartis Pharmaceuticals
Other Metastatic Colorectal Cancer trials with similar outcome
Listed as NCT04952753, this PHASE2 trial focuses on Metastatic Colorectal Cancer and remains terminated or withdrawn. Sponsored by Novartis Pharmaceuticals, it has been updated 28 times since 2021, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
28 versions recorded-
Dec 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2025 — Dec 2025 [monthly]
Terminated PHASE2
-
Apr 2025 — Sep 2025 [monthly]
Terminated PHASE2
Status: Completed → Terminated
-
Feb 2025 — Apr 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Dec 2024 — Feb 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 23 earlier versions
-
Nov 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE2
-
Oct 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Apr 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Active Not Recruiting PHASE2
-
Jan 2024 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
-
Nov 2023 — Jan 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
Sep 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE2
-
Feb 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Nov 2022 — Feb 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE2
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE2
-
Jan 2022 — Apr 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2021 — Jan 2022 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2021 — Dec 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aberdeen, United Kingdom , Adelaide, Australia , Ann Arbor, United States , Avignon, France , Barcelona, Spain , Bendigo, Australia , Berlin, Germany , Bochum, Germany , Brampton, Canada , Brno, Czechia and 41 more locations